非血缘供者年龄与HLA肽结合基序匹配状态对造血干细胞移植结局的联合影响
该研究比较了6组不同HLA匹配状态与供者年龄(≤35岁 vs >35岁)组合下接受常规移植物抗宿主病预防的造血干细胞移植患者的结局。多变量分析显示HLA匹配/年轻供者组总生存最优,供者年龄在HLA匹配和错配组均显著影响总生存,年轻供者似乎可抵消PBM错配的不良影响。研究提示供者年龄较大与PBM错配带来相似的生存不良影响且效应叠加,最佳总生存见于HLA匹配/年轻供者组,最差见于PBM错配/年长供者组。
要点
- HLA匹配/年轻供者组总生存优于其他任何组。
- 年轻供者似乎可抵消PBM错配的不良影响。
- 供者年龄较大与PBM错配的不良影响相似且叠加。
核心结论
- 供者年龄较大与PBM错配带来相似的生存不良影响且效应叠加,这一发现可能拓宽「可接受」供者池。
- 最佳总生存见于HLA匹配/年轻供者组,最差见于PBM错配/年长供者组。
- 这些发现需用其他数据集及基于移植后环磷酰胺的预防方案进行验证。
研究设计与样本
- 研究比较了6组接受常规移植物抗宿主病预防的造血干细胞移植患者:HLA匹配/年轻供者组(n=10531)、HLA匹配/年长供者组(n=3572)、PBM匹配/年轻供者组(n=357)、PBM匹配/年长供者组(n=257)、PBM错配/年轻供者组(n=616)、PBM错配/年长供者组(n=339)。
主要发现
- 多变量分析中,HLA匹配/年轻供者组总生存优于其他任何组。
- 成对比较显示,供者年龄在HLA匹配组和HLA错配组均显著影响总生存。
- PBM匹配/年轻供者组与HLA匹配/年长供者组总生存相似。
- PBM错配/年轻供者组与PBM匹配/年长供者组总生存相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现需用其他数据集及基于移植后环磷酰胺的预防方案进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An HLA-mismatched unrelated donor who is class I peptide-binding motif (PBM)-matched is preferred over a PBM-mismatched donor. We hypothesized that using a younger donor (aged ≤35 years vs >35 years) could compensate for the inferior overall survival (OS) associated with PBM mismatches. We compared 6 groups: HLA-matched/younger donor (n = 10 531), HLA-matched/older donor (n = 3572), PBM-matched/younger donor (n = 357), PBM-matched/older donor (n = 257), PBM-mismatched/younger donor (n = 616), and PBM-mismatched/older donor (n = 339) in patients undergoing transplantation with conventional graft-versus-host disease prophylaxis. In multivariate analysis, HLA-matched/younger donors were associated with superior OS relative to any other group. Pairwise comparisons showed that donor age significantly impacted OS in both HLA-matched and HLA-mismatched groups. Moreover, younger donors appeared to negate the detrimental effect of PBM mismatching: the PBM-matched/younger donor group had similar OS as the HLA-matched/older donor group and the PBM-mismatched/younger donor group had similar OS as the PBM-matched/older donor group. Our study suggests that older unrelated donor age and PBM mismatching confer similarly adverse effects on OS and the impacts are additive, a finding which may widen the "acceptable" donor pool. The best OS is observed with HLA-matched/younger donors and the worst with PBM-mismatched/older donors. These findings should be validated with other data sets and with posttransplantation cyclophosphamide-based prophylaxis.
引用
- Mehta RS, Petersdorf EW, Spellman SR, et al. Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes. Blood Adv. 2024. PMID: 38467032. doi:10.1182/bloodadvances.2024012669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。